Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.68 |
| ▸ | NAAA | Q02083 | 1/20 | 0.63 |
| ▸ | FAAH | O00519 | 5/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.56 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28492153 | 0.90 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1 | |
| SCHEMBL2417623 | 0.88 | CASP2 (0.55) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL25894622 | 0.86 | CASP2 (0.71) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL21633848 | 0.85 | CASP2 (0.83) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL22271678 | 0.85 | CASP2 (0.83) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL23775006 | 0.85 | CASP2 (0.83) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL20542645 | 0.85 | CASP2 (0.83) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL21234011 | 0.85 | CASP2 (0.83) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL18733370 | 0.85 | CASP2 (0.83) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL1786723 | 0.85 | CASP2 (0.83) | CASP2NAAAFAAHEPHX1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173995-A1 | Use of PPAR-alpha activator as inflammatory skin disease-treating agent and method for treating skin diseases using the same | NEOPHARM CO., LTD. | 2010-07-08 | — | — | US | claimed |
| US-20100173995-A1 | Use of PPAR-alpha activator as inflammatory skin disease-treating agent and method for treating skin diseases using the same | NEOPHARM CO., LTD. | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173995-A1 | Use of PPAR-alpha activator as inflammatory skin disease-treating agent and method for treating skin diseases using the same | PPARA, PPARG, PPARD | CASP2 853/4885NAAA 1222/4885FAAH 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.